AstriVax Therapeutics Initiates Clinical Development of
Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential first-in-class treatment that could form part of functional cure for over 250 million patients suffering from chronic hepatitis B virus (HBV) infection Leuven, Belgium, June 5, … Read more